UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Journal of thrombosis and haemostasis, 2015-05, Vol.13 (5), p.743-754

2015

Volltextzugriff (PDF)

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A

Journal of thrombosis and haemostasis, 2018-11, Vol.16 (11), p.2184-2195

2018

Volltextzugriff (PDF)

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

Journal of thrombosis and haemostasis, 2012-04, Vol.10 (4), p.622-631

2012

Volltextzugriff (PDF)

Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry

BJOG : an international journal of obstetrics and gynaecology, 2012-11, Vol.119 (12), p.1529-1537

2012

Volltextzugriff (PDF)

OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL

Hematology, Transfusion and Cell Therapy, 2020-11, Vol.42, p.95-95

2020

Volltextzugriff (PDF)

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

Journal of thrombosis and haemostasis, 2012-08, Vol.10 (8), p.1581-1590

2012

Volltextzugriff (PDF)

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

International journal of antimicrobial agents, 2010-12, Vol.36 (6), p.531-536

2010

Volltextzugriff (PDF)

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES

HemaSphere, 2022-06, Vol.6 (Suppl), p.2175-2176

2022

Volltextzugriff (PDF)

TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S458-S459

2023

Volltextzugriff (PDF)

Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-09, Vol.17 (5), p.e889-e894

2011

Volltextzugriff (PDF)

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

Hematology, Transfusion and Cell Therapy, 2020-10, Vol.42, p.62-63

2020

Volltextzugriff (PDF)

Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study

Hematology, Transfusion and Cell Therapy, 2020-10, Vol.42, p.62-62

2020

Volltextzugriff (PDF)

Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial

Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2159-2167

2011

Volltextzugriff (PDF)

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

Journal of thrombosis and haemostasis, 2017-07, Vol.15 (7), p.1448-1452

2017

Volltextzugriff (PDF)

OC 14.5 Plasma Exchange-free Management of Immune Thrombotic Thrombocytopenic Purpura: The Austrian-German Experience

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.100532, Article 100532

2023

Volltextzugriff (PDF)

High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.405-413

2018

Volltextzugriff (PDF)

Consensus statement for cancer patients requiring intensive care support

Annals of hematology, 2018-07, Vol.97 (7), p.1271-1282

2018

Volltextzugriff (PDF)

NET untangled in TMA?

Journal of thrombosis and haemostasis, 2015-05, Vol.13 (5), p.729-731

Knobl, P

2015

Volltextzugriff (PDF)

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study

Journal of thrombosis and haemostasis, 2016-05, Vol.14 (5), p.940-947

2016

Volltextzugriff (PDF)

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

Journal of thrombosis and haemostasis, 2011-05, Vol.9 (5), p.936-944

2011

Volltextzugriff (PDF)

OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.100534, Article 100534

2023

Volltextzugriff (PDF)

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

Blood, 2016-12, Vol.128 (22), p.135-135

2016

Volltextzugriff (PDF)

LB 01.2 Emicizumab Prophylaxis Instead of Immunosuppressive Therapy in Patients with Acquired Hemophilia A (AHA)

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.100289, Article 100289

2023

Volltextzugriff (PDF)

Treatment of thrombotic microangiopathy with a focus on new treatment options

Hämostaseologie, 2013-05, Vol.33 (2), p.149-159

Knöbl, P N

2013

Volltextzugriff (PDF)

PB0313 Towards the Standardisation of ADAMTS-13 Antibody Testing in Thrombotic Thrombocytopenic Purpura (TTP)-Results of the IMATAS Collaborative Study

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.101473, Article 101473

2023

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Aktive Filter

PublikationsformArtikel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(59)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(54)
Science & Technology
(54)
Humans
(40)
Hematology
(31)
Female
(27)
Male
(27)
Middle Aged
(24)
Adult
(22)
Biological And Medical Sciences
(21)
Aged
(19)
Cardiovascular System & Cardiology
(19)
Medical Sciences
(19)
Peripheral Vascular Disease
(18)
Treatment Outcome
(15)
Hematologic And Hematopoietic Diseases
(10)
Animals
(9)
Prospective Studies
(8)
Young Adult
(8)
Adolescent
(7)
Oncology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry

OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES

TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY

Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study

Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

OC 14.5 Plasma Exchange-free Management of Immune Thrombotic Thrombocytopenic Purpura: The Austrian-German Experience

High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)

Consensus statement for cancer patients requiring intensive care support

NET untangled in TMA?

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

LB 01.2 Emicizumab Prophylaxis Instead of Immunosuppressive Therapy in Patients with Acquired Hemophilia A (AHA)

Treatment of thrombotic microangiopathy with a focus on new treatment options

PB0313 Towards the Standardisation of ADAMTS-13 Antibody Testing in Thrombotic Thrombocytopenic Purpura (TTP)-Results of the IMATAS Collaborative Study

Aktive Filter

Suchergebnisse filtern